DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Upadacitinib
Drug: Placebo

First Posted Date: 2016-10-05

Last Posted Date: 2020-07-16

Lead Sponsor: AbbVie

Target Recruit Count: 167

Registration Number: NCT02925117

Locations: 🇺🇸
Advanced Medical Research /ID# 154516, Sandy Springs, Georgia, United States
🇺🇸
ForCare Clinical Research /ID# 157974, Tampa, Florida, United States
🇺🇸
DermAssociates /ID# 153584, Rockville, Maryland, United States

and more 31 locations

HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis

Completed

Conditions: Uveitis

First Posted Date: 2016-09-27

Last Posted Date: 2021-10-14

Lead Sponsor: AbbVie

Target Recruit Count: 259

Registration Number: NCT02916017

Locations: 🇯🇵
Nippon Medical School Hospital /ID# 166938, Bunkyo-ku, Tokyo, Japan
🇯🇵
The University of Tokyo Hospital /ID# 162943, Bunkyo-ku, Tokyo, Japan
🇯🇵
Tokyo Medical University Hospital /ID# 164146, Shinjuku-ku, Tokyo, Japan

and more 36 locations

Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease

Active, not recruiting

Conditions: Parkinson's Disease

First Posted Date: 2016-09-20

Last Posted Date: 2024-06-18

Lead Sponsor: AbbVie

Registration Number: NCT02906488

Locations: 🇯🇵
Fukui Red Cross Hospital /ID# 166907, Fukui-shi, Fukui, Japan
🇯🇵
National Hospital Organization Takasaki General Medical Center /ID# 207773, Takasaki-shi, Gunma, Japan
🇯🇵
Muroran-Clinic /ID# 207780, Muroran-shi, Hokkaido, Japan

and more 112 locations

Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa

Phase 3

Completed

Conditions: Hidradenitis Suppurativa

Interventions: Drug: adalimumab

First Posted Date: 2016-09-19

Last Posted Date: 2020-05-12

Lead Sponsor: AbbVie

Target Recruit Count: 15

Registration Number: NCT02904902

Locations: 🇯🇵
Fukuoka University Hospital /ID# 151350, Fukuoka, Japan
🇯🇵
Takagi Dermatological Clinic /ID# 151906, Obihiro, Hokkaido, Japan
🇯🇵
Kurume University Hospital /ID# 152579, Kurume-shi, Fukuoka, Japan

and more 5 locations

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Venetoclax
Drug: Dexamethasone

First Posted Date: 2016-09-14

Last Posted Date: 2024-04-16

Lead Sponsor: AbbVie

Target Recruit Count: 120

Registration Number: NCT02899052

Locations: 🇺🇸
Oncology Hematology Associates (OHA) - Springfield /ID# 218855, Springfield, Missouri, United States
🇺🇸
University of Pennsylvania /ID# 151768, Philadelphia, Pennsylvania, United States
🇺🇸
University of Texas Southwestern Medical Center /ID# 218336, Dallas, Texas, United States

and more 29 locations

A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment

Phase 4

Terminated

Conditions: Axial Spondyloarthritis

Interventions: Biological: Adalimumab
Other: Non-steroidal Anti-inflammatory Drugs (NSAIDs)

First Posted Date: 2016-09-13

Last Posted Date: 2019-07-05

Lead Sponsor: AbbVie

Target Recruit Count: 22

Registration Number: NCT02897115

Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness

Completed

Conditions: Hidradenitis Suppurativa (HS)

First Posted Date: 2016-09-12

Last Posted Date: 2020-05-01

Lead Sponsor: AbbVie

Target Recruit Count: 165

Registration Number: NCT02896920

Locations: 🇨🇦
Alberta DermaSurgery Centre /ID# 153834, Edmonton, Alberta, Canada
🇨🇦
Institute for Skin Advancement /ID# 152448, Calgary, Alberta, Canada
🇨🇦
Dre. Angelique Gagne-Henley /ID# 152611, St-Jerome, Quebec, Canada

and more 19 locations

Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA )

Completed

Conditions: Crohn's Disease

First Posted Date: 2016-09-12

Last Posted Date: 2021-03-09

Lead Sponsor: AbbVie

Target Recruit Count: 98

Registration Number: NCT02896985

Locations: 🇨🇦
Columbia Gastro Mgmnt Ltd /ID# 152507, New Westminster, British Columbia, Canada
🇨🇦
GIRI Gastrointestinal Research Institute /ID# 201259, Vancouver, British Columbia, Canada
🇨🇦
Percuro Clinical Research, Ltd /ID# 202502, Victoria, British Columbia, Canada

and more 21 locations

A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: ABBV-8E12
Drug: placebo for ABBV-8E12

First Posted Date: 2016-08-26

Last Posted Date: 2022-08-26

Lead Sponsor: AbbVie

Target Recruit Count: 453

Registration Number: NCT02880956

Locations: 🇺🇸
Irvine Clinical Research /ID# 162331, Irvine, California, United States
🇺🇸
Brain Matters Research /ID# 147796, Delray Beach, Florida, United States
🇺🇸
Neuropsychiatric Research Center of Southwest Florida /ID# 162332, Fort Myers, Florida, United States

and more 65 locations

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 2016-08-01

Last Posted Date: 2019-09-18

Lead Sponsor: AbbVie

Target Recruit Count: 66

Registration Number: NCT02851069

Locations: 🇨🇴
Centro Medico lmbanaco de Cali I, Cali, Colombia
🇨🇴
Fundacion Hospitalaria San Vin, Medellín, Colombia
🇨🇴
Cic Cali, Cali, Colombia

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy